MedPage Today Investigative Reports and Medical Controversies
MedPage Today has established itself as a provocative voice in medical journalism, frequently publishing deep-dive analyses and investigative reports that challenge established pharmaceutical practices, insurance protocols, and clinical standards. From examining the opioid crisis to questioning the efficacy of diabetes care, these reports often spark intense debate within the medical community.
Key Facts
- Opioid Influence: Investigations revealed a $2.5 million undisclosed payment from drug manufacturers to the UW Pain & Policy Studies Group to promote opioid use.
- FDA Action: Reports on Opana ER contributed to the FDA removing the drug from the market in June 2017.
- Diabetes Trends: A 2017 analysis highlighted a rise in amputation cases among diabetes patients starting in 2013.
- Insurance Critique: The "dinner table stories" report exposed controversial preauthorization processes in the insurance industry.
- Suicide Analysis: A 2018 report attributed rising U.S. suicide rates to a lack of clinical training among physicians.
Investigations into Opioid Painkillers and Pharmaceutical Influence
Between 2011 and 2012, a joint investigation by MedPage Today and the Milwaukee Journal Sentinel scrutinized the financial ties between narcotic painkiller manufacturers and nonprofit advocacy organizations. A primary focus of this investigation was the UW Pain & Policy Studies Group, based at the University of Wisconsin-Madison. The report alleged that this group received $2.5 million in undisclosed funds from pharmaceutical companies to advocate for the increased prescription of opioid-based drugs.
This journalistic effort gained significant traction when the U.S. Senate Committee investigated the merits of the claims. Max Baucus, chairman of the committee, described the situation as an epidemic of addiction and accidental deaths. While the broader practice of prescribing opioids was criticized, the drug OxyContin, produced by Purdue Pharma, was a central point of discussion.
Further investigations in 2015 focused on Opana ER, highlighting a troubled FDA approval history and widespread abuse. Following the fallout from this reporting, the FDA removed Opana ER from the market in June 2017. This marked the second time the drug was withdrawn, following a previous removal in 1979 due to abuse patterns seen in the 1960s and 1970s.
Clinical Trends and Healthcare System Critiques
Beyond pharmaceuticals, MedPage Today has analyzed systemic failures in patient care. In October 2017, Cheryl Clark published a statistical and clinical analysis regarding the increasing rate of amputations in patients with diabetes from 2013 onwards. The findings were met with mixed reactions from medical professionals.
The publication also targeted the insurance industry in November 2017. A report detailing the inner workings of insurance machinery—often referred to as "dinner table stories"—criticized the preauthorization process (the requirement that a healthcare provider obtain approval from an insurance company before a specific service is rendered). While some praised the report for exposing unethical practices, others questioned its factual accuracy.
Debates on Physician Accountability and Suicide Rates
In September 2018, MedPage Today released a controversial analysis on the rising suicide rates in the United States. The report argued that medical professionals, specifically physicians, bore responsibility due to a lack of clinical training. By attempting to fix accountability on the failure of physicians in general, the report faced severe backlash and was largely rejected by the medical community.
| Topic | Key Finding/Event | Outcome/Reaction |
|---|---|---|
| Opioid Funding | $2.5M undisclosed payment to UW Group | U.S. Senate Committee investigation |
| Opana ER | History of abuse and approval issues | FDA market removal (June 2017) |
| Diabetes Care | Rise in amputations since 2013 | Mixed medical reception |
| Insurance | Unethical preauthorization practices | Controversy over factual accuracy |
| Suicide Rates | Blamed on physician training gaps | Rejected by most medical professionals |
Frequently Asked Questions
What was the controversy surrounding the UW Pain & Policy Studies Group?
The group was accused of receiving $2.5 million in undisclosed funds from pharmaceutical companies to promote the use and prescription of opioid-based painkillers.
Why was Opana ER removed from the market in 2017?
The drug was removed by the FDA following reports of pervasive abuse and a troubled approval history, echoing a previous removal in 1979.
What are "dinner table stories" in the context of medical reporting?
This term refers to a November 2017 report by MedPage Today that criticized the unethical functioning of insurance machinery and the preauthorization process.
How did the medical community react to the 2018 report on suicide rates?
Most medical professionals rejected the report's hypothesis, which blamed the rising rate of suicides in the U.S. on the lack of clinical training among physicians.
Which pharmaceutical company was specifically mentioned during the Senate Committee's opioid discussion?
The discussion focused heavily on the drug OxyContin, which is manufactured by Purdue Pharma.